Tablet: Reproduction studies in animals (mice & rats) with parenterally administered INDCLAV* have shown no teratogenic effects. There is limited experience of the use of INDCLAV* in human pregnancy. As with all medicines, use should be avoided in pregnancy especially during the first trimester. Unless considered essential by the physician, INDCLAV* may be administered during the period of lactation. With the exception of the risk sensitization associated with the excretion of trace quantities in breast milk, there are no detrimental effects for the infant.